← Braveheart Bio, Inc. (BRVE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Braveheart Bio, Inc. (BRVE)
Pharmaceutical Preparations · market cap $2.1B · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-08 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Braveheart Bio (BRVE) is a Pharmaceutical Preparations company with a roughly $1.97B market cap (~90.0M shares at ~$21.87). Its only pipeline asset in our data is BHB-1893, in Phase 3 for hypertrophic obstructive cardiomyopathy (oHCM). Our calendar shows only an estimated Dec 8, 2026 earnings date, and no recent catalysts are recorded.
The catalyst path
- 2026-12-08 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BHB-1893 | Phase 3 | Cardiomyopathy, Hypertrophic Obstructive |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$18.58–$30.00
vs 50-day MA
-9.7%
vs 200-day MA
—
Realized vol
82.2%
Max drawdown
-38.1%
Daily closes through 2026-10-28. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BRVE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.